Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Carbamazepine
Drug ID BADD_D00356
Description Carbamazepine, also known as Tegretol, is an anticonvulsant drug and analgesic drug used to control seizures and to treat pain resulting from trigeminal neuralgia. It was initially approved by the FDA in 1965.[A180301] Aside from the above uses, this drug is also given to control the symptoms of bipolar 1.[L1335] Interestingly, carbamazepine was the first anticonvulsant used to treat individuals with bipolar disorder.[A180319]
Indications and Usage Carbamazepine is indicated for the treatment of epilepsy and pain associated with true trigeminal neuralgia.[L1335] In particular, carbamazepine has shown efficacy in treating mixed seizures, partial seizures with complex symptoms, and generalized tonic-clonic seizures.[A180301,L1335] Carbamazepine is also indicated for the treatment of manic episodes and mixed manic-depressive episodes caused by bipolar I disorder.[L1335] Some off-label, unapproved uses of carbamazepine include the treatment of alcohol withdrawal syndrome and restless leg syndrome.[A180415,A180421]
Marketing Status approved; investigational
ATC Code N03AF01
DrugBank ID DB00564
KEGG ID D00252
MeSH ID D002220
PubChem ID 2554
TTD Drug ID D04MSM
NDC Product Code 62512-0024; 30698-421; 50268-172; 60687-583; 63629-9292; 66993-409; 70518-3266; 70771-1470; 0615-8125; 0781-5987; 0904-6885; 49452-1705; 63552-060; 0078-0510; 0078-0511; 16571-681; 16714-064; 0093-0778; 17856-0029; 29033-019; 30698-419; 35561-355; 50090-0384; 51672-4047; 51672-4151; 54092-173; 60429-934; 60687-594; 63629-8721; 70518-0181; 70771-1469; 70954-240; 71205-025; 75834-220; 12658-0525; 12658-0526; 0904-7116; 42419-014; 35561-357; 51672-4149; 54092-171; 59746-789; 60505-2805; 63629-8743; 66993-407; 67386-621; 68788-7210; 70518-1433; 59746-790; 63629-8753; 68084-562; 68382-557; 70518-3176; 0781-5988; 16714-063; 27241-233; 29033-004; 29300-382; 35561-356; 51407-215; 60505-2807; 70518-1545; 71930-073; 72162-2021; 0781-8016; 0832-6022; 12658-0561; 12658-0565; 48087-0051; 70966-0020; 76003-0251; 13668-268; 0093-0109; 27241-232; 43063-328; 50268-170; 54092-172; 60505-2806; 68788-7825; 70518-1436; 70518-2242; 70518-3335; 71335-0461; 71335-0691; 71930-072; 75834-221; 0904-3854; 51927-2176; 13668-271; 51672-4125; 63629-8715; 68084-444; 68382-555; 70518-1769; 70518-2456; 70518-3699; 70518-3773; 0832-6023; 12658-0452; 51552-0653; 62991-1027; 65344-0028; 65344-0040; 0078-0512; 27241-231; 0121-0947; 43353-953; 59746-791; 70518-2426; 70518-3146; 71930-074; 72189-157; 0904-6172; 12658-0406; 12658-0541; 0078-0509; 0093-0090; 29033-020; 51672-4005; 51672-4123; 55154-1396; 60505-0183; 60687-479; 63629-8720; 68094-007; 68382-556; 70518-2841; 70518-3591; 70518-3694; 71335-1730; 12658-0486; 38779-0114; 48087-0052; 0078-0508; 16714-065; 30698-423; 50268-171; 51672-4150; 58118-0268; 66993-408; 68071-2701; 70518-2489; 70518-3174; 70771-1468; 0615-3505; 72664-218; 0832-6024; 65372-1102; 16571-680; 16571-682; 0121-1894; 50090-5740; 51672-4041; 51672-4124; 60429-032
UNII 33CM23913M
Synonyms Carbamazepine | Carbamazepine Acetate | Carbamazepine Dihydrate | Carbamazepine Hydrochloride | Carbamazepine L-Tartrate (4:1) | Carbamazepine Anhydrous | Carbamazepine Sulfate (2:1) | Carbazepin | Epitol | Finlepsin | Neurotol | Tegretol | Amizepine | Carbamazepine Phosphate
Chemical Information
Molecular Formula C15H12N2O
CAS Registry Number 298-46-4
SMILES C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Sinus bradycardia02.03.03.0090.001227%
Sinus tachycardia02.03.03.0100.000651%
Sinusitis22.07.03.007; 11.01.13.005--
Sjogren's syndrome15.06.01.015; 10.04.04.009; 07.06.01.010; 06.08.02.0110.000186%Not Available
Skin depigmentation23.05.02.002--Not Available
Skin discolouration23.03.03.0050.001023%Not Available
Skin disorder23.03.03.0070.000967%Not Available
Skin erosion23.07.03.0020.001209%Not Available
Skin exfoliation23.03.07.0030.004966%Not Available
Skin fissures23.03.03.0080.000186%Not Available
Skin hyperpigmentation23.05.01.0030.000465%
Skin lesion23.03.03.0100.002232%Not Available
Skin necrosis23.03.03.0110.000186%Not Available
Skin reaction23.03.03.013; 10.01.03.0190.001432%Not Available
Skin ulcer24.04.03.007; 23.07.03.0030.000651%
Skin warm23.03.03.014--Not Available
Sluggishness08.01.01.0040.000186%Not Available
Social avoidant behaviour19.05.01.0070.000279%Not Available
Somnambulism19.02.03.006; 17.15.02.0040.000186%Not Available
Somnolence19.02.05.003; 17.02.04.0060.016440%
Speech disorder22.12.03.027; 19.19.02.002; 17.02.08.0030.002920%Not Available
Spermatogenesis abnormal21.03.03.002--Not Available
Splenomegaly01.09.02.0010.000558%Not Available
Status epilepticus17.12.03.0050.003720%Not Available
Stevens-Johnson syndrome10.01.01.045; 23.03.01.007; 12.03.01.014; 11.07.01.0050.010880%
Stillbirth18.01.02.002; 08.04.01.0060.003905%Not Available
Stomatitis07.05.06.005--
Strabismus17.17.01.009; 06.05.02.0040.000372%Not Available
Stupor19.02.05.004; 17.02.04.0070.000186%Not Available
Suicidal ideation19.12.01.003--
The 20th Page    First    Pre   20 21 22 23 24    Next   Last    Total 32 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene